BE Biosol, Gates Foundation Ink Pact for FCM Anemia Injection

The agreement concerns the development of Ferric Carboxymaltose (FCM) injection and improving the availability of the drug in many countries. | Photo credit: Arrangement

BE Biosol, the CDMO subsidiary of vaccine manufacturer Biological E., has entered into an agreement with the Gates Foundation to develop Ferric Carboxymaltose (FCM) injection and to improve the availability of the drug for the treatment of iron deficiency anemia in many countries.

The Gates Foundation will support BE Biosol for the expansion and clinical development of the product for target markets. BE Biosol will use its research and development capabilities and manufacturing infrastructure to support the program, the company said in a news release on the agreement to expand access to FCM injection in Africa.

BE Biosol aims to create a differentiated, cost-competitive offering and build a meaningful market presence by leveraging its manufacturing scale and proprietary API technology. The collaboration with the Gates Foundation reflects confidence in BE Biosol’s ability to develop and manufacture high-tech sterile products at competitive cost and scale. More broadly, this reinforces the company’s strategy to establish itself as a globally competitive CDMO platform across complex biologics and pharmaceutical modalities, said Narender Mantena, Chief Executive Officer.

BE Biosol’s manufacturing facility is in Shamirpet, Telangana. Since its launch in 2018, it has passed numerous inspections and received multiple approvals from leading regulatory agencies, including the US FDA, Infarmed (Portugal), UK MHRA and Brazil’s ANVISA, the company said in a release.

Published – 19 Nov 2026 20:44 IST